Skip to content
Search

Latest Stories

NHS asks employers to hold virus risk assessments for BAME pharmacy teams within weeks

The NHS has asked hospital trusts, clinical commissioning groups, general practices and community pharmacies to conduct risk assessments within two weeks to ensure safety of vulnerable staff including black, Asian and minority ethnic (BAME) workers.

In a letter to the employers last week, the NHS directed all organisations to finish the risk assessment of all BAME staff members within a month.


The letter has asked the employers to publish data on their staff including,

• Number of staff risk-assessed and percentage of whole workforce.

• Number of black, Asian and minority ethnic (BAME) staff risk assessments completed, and percentage of total risk assessments completed and of whole workforce

• Percentage of staff risk-assessed by staff group

• Additional mitigation over and above the individual risk assessments in settings where infection rates are highest.

The letter added that the information on the implementation of risk assessment should be shared with the healthcare workers including pharmacists.

“We also ask that these data become part of your board assurance framework (or equivalent in a primary care context) and receive board-level scrutiny and ownership. For primary care providers, this would be a senior partner or the business owner as the employer with overall responsibility for their workforce,” the letter pointed out.

All primary care organisations remain legally responsible for securing appropriate occupational health (OH) assessments including staff risk assessments for their employees.

The employers may continue to use customised tools developed locally with their BAME networks.

In a response to the NHS letter, the Royal Pharmaceutical Society (RPS) on Monday (June 29) said that it expects healthcare organisations, including pharmacies, to take necessary Covid-19 risk assessments to ensure the safety of their BAME staff members.

Ravi Sharma, RPS Director for England, said: "We are pleased to see NHS England taking swift action following the findings of our survey. Risk assessments are essential to ensure that pharmacists and their teams are safe and protected at work. Employers have a duty of care to their employees and we hope to see them act responsibly and take action in response to this letter as a matter of urgency.

“We know the risks of serious complications from Covid-19 - including death - are higher for those from the BAME community. Now is the time for action from employers to build confidence across the profession that this issue is being tackled. "

The latest letter by the NHS follows an RPS and UK Black Pharmacists Association survey which found that over two-thirds of BAME pharmacists had not had workplace risk assessments for coronavirus.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less